10-Q: Avalo Therapeutics Reports Q1 2024 Results, Completes Acquisition and Private Placement

Avalo Therapeutics completed a merger to acquire AVTX-009 and closed a significant private placement, while reporting a substantial net loss for the first quarter of 2024.

Summary

• Avalo Therapeutics reported a net loss of $121.3 million for the first quarter of 2024, compared to a net loss of $9.955 million in the same period of 2023.
• The company's operating expenses totaled $32.767 million, which included a significant $27.538 million expense for acquired in-process research and development related to the acquisition of AVTX-009.
• Avalo completed a merger with AlmataBio, acquiring AVTX-009, a Phase 2-ready anti-IL-1 mAb, on March 27, 2024.
• The company closed a private placement on March 28, 2024, raising $115.6 million in gross proceeds, with potential for an additional $69.4 million upon warrant exercises.
• As of March 31, 2024, Avalo had $110.2 million in cash and cash equivalents, which they expect to fund operations into 2027.
• The company's warrant liability was valued at $194.901 million, resulting in a $79.276 million loss due to the excess of warrant fair value over private placement proceeds.
• There was no net product revenue for the three months ended March 31, 2024, compared to $0.475 million for the same period in 2023 due to the expiration of the Millipred license.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the acquisition and private placement are positive developments, the substantial net loss and warrant liability are concerning. The company's long cash runway is a positive, but the overall sentiment is neutral to slightly negative due to the financial losses.

Positives

• The acquisition of AVTX-009 adds a Phase 2-ready asset to Avalo's pipeline.
• The private placement provides substantial funding to support operations and development plans.
• The company expects its current cash to fund operations into 2027, providing a long runway for development.
• The company has a clear strategy for increasing stockholder value, including advancing its pipeline and out-licensing opportunities.

Negatives

• Avalo reported a significant net loss of $121.3 million for the first quarter of 2024.
• The warrant liability resulted in a substantial loss of $79.276 million.
• Operating expenses increased significantly due to the acquired in-process research and development expense.
• There was no net product revenue for the three months ended March 31, 2024, compared to $0.475 million for the same period in 2023.

Risks

• The company has incurred significant operating and cash losses since inception.
• Future cash needs may require additional sales of equity securities, which could dilute existing stockholders.
• There is no assurance that financing or business development initiatives can be realized.
• The company may need to relinquish valuable rights to its technologies or future revenue streams to raise capital.
• The warrant liability is subject to fluctuations based on the company's stock price and other factors.
• The company is subject to risks associated with the development of pharmaceutical products, including regulatory hurdles and clinical trial outcomes.

Future Outlook

Avalo expects its existing cash and cash equivalents to fund operations for at least twelve months from the filing date of this report and into 2027. The company may need to raise additional funds through various means, including sales of equity securities, out-licensing, strategic alliances, or mergers and acquisitions.

Management Comments

• Management's primary evaluation of the success of the Company is the ability to progress its pipeline assets forward towards commercialization or opportunistically out-licensing rights to indications or geographies.
• We believe the ability to achieve the anticipated milestones as presented in the following chart represents our most immediate evaluation points as to the progress of our goal to move the pipeline forward.

Industry Context

The acquisition of AVTX-009 and the private placement are significant steps for Avalo in the competitive biotechnology industry. The company is focused on advancing its pipeline of compounds through development and to regulatory approval, which is a common strategy in the sector. The company's focus on immune dysregulation is also aligned with current trends in the pharmaceutical industry.

Comparison to Industry Standards

• Avalo's Q1 2024 net loss of $121.3 million is substantial, especially when compared to the $9.955 million loss in Q1 2023. This indicates a significant increase in expenses, primarily due to the acquisition of AVTX-009.
• The $27.538 million expense for acquired in-process research and development is a significant one-time cost, which is not uncommon for biotech companies acquiring new assets.
• The $194.901 million warrant liability and the resulting $79.276 million loss are unusual and reflect the specific terms of the private placement. This is not a typical financial metric for most biotech companies.
• The company's cash position of $110.2 million is relatively strong, especially given the expectation that it will fund operations into 2027. This is a positive sign compared to many other clinical-stage biotech companies that often face near-term funding challenges.
• The lack of product revenue in Q1 2024, compared to $0.475 million in Q1 2023, is a result of the expiration of the Millipred license. This is not unusual for biotech companies that are transitioning from commercializing older assets to focusing on new pipeline products.
• Compared to other clinical-stage biotech companies, Avalo's financial results are mixed. The company has secured significant funding and a promising new asset, but it also faces substantial losses and a complex financial structure due to the warrant liability. Companies like BioMarin Pharmaceutical Inc. and Vertex Pharmaceuticals Incorporated, which have commercialized products, have more stable revenue streams and lower losses, while companies like CRISPR Therapeutics AG and Editas Medicine, Inc., which are also in the clinical stage, have similar challenges with high R&D expenses and losses.

Legal Proceedings

• On January 25, 2024, the Company and Apollo entered into a settlement and release agreement, pursuant to which Avalo agreed to pay Apollo $0.2 million to settle a dispute.

Related Party Transactions

• In July 2019, Aevi entered into a royalty agreement with certain investors, including LeoGroup Private Investment Access, LLC on behalf of Garry Neil, the Companys Chief Executive Officer and Chairman of the Board, and Mike Cola, the Companys former Chief Executive Officer.

Stakeholder Impact

• Shareholders will experience dilution if the company raises additional capital through equity sales.
• Employees may benefit from the company's increased financial stability and pipeline development.
• Customers may benefit from the development of new therapies.
• Suppliers and creditors may benefit from the company's improved financial position.

Next Steps

• The company will continue to monitor the milestones at each reporting period.
• The company will continue to monitor estimates for commercial liabilities, such as sales returns.
• The company will continue to monitor the third milestone payment due to the former AlmataBio stockholders.
• The company will continue to monitor the second milestone payment due to the Aevi merger.
• The company will continue to monitor the milestones under the AVTX-009 agreements.
• The company will continue to monitor the milestones under the KKC License Agreement.
• The company will continue to monitor the milestones under the Sanford Burnham Prebys License Agreement.
• The company will continue to monitor the remaining milestones under the Astellas License Agreement.

Key Dates

Keywords

AVTX-009, private placement, acquisition, biotechnology, clinical stage, monoclonal antibody, immune dysregulation, warrant liability, net loss, research and development